Back to top

Analyst Blog

Auxilium Pharmaceuticals (AUXL - Analyst Report) currently has two approved products – Testim and Xiaflex (EU trade name: Xiapex) – in its portfolio in the U.S.

Testim (1% testosterone) is approved for the treatment of hypogonadism or low testosterone level, whereas Xiaflex is an injectable enzyme (clostridial collagenase for injection) currently approved for the treatment of Dupuytren’s Contracture (DC).

We note that Auxilium Pharma is developing Xiaflex in collaboration with BioSpecifics Technologies Corp. . The company is currently working to expand Xiaflex label.

Auxilium Pharma announced encouraging results on Xiaflex from the MULTICORD (Multiple Treatment Investigation of Collagenase Optimizing the Resolution of Dupuytren's) study.

Results from the phase III study (n=715) showed that two concurrent injections of Xiaflex in patients with multiple DC led to a significant improvement in joint contracture and the range of motion as compared to single injections administered in a gap of 30 days.

The study also showed that concurrent injections of Xiaflex reduced total fixed flexion contracture (FFC) by an average of 74.4% and improved the total range of motion by a combined average 66.6 degrees. 

Hence, Auxilium Pharma intends to submit the planned supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) in the first quarter of 2014, backed by positive results from various MULTICORD studies. The company is seeking label expansion of Xiaflex for the concurrent treatment of multiple palpable cords.

We remind investors that Auxilium Pharma is also seeking FDA approval for the use of Xiaflex in the treatment of Peyronie’s disease – a sBLA has been submitted for the same. Meanwhile, Xiaflex is in a phase IIa study for the treatment of cellulite.

We are encouraged by Auxilium Pharma's efforts to expand Xiaflex' label. Xiaflex generated sales of $57.1 million in the first nine months of 2013, up 26.6% from the year-ago period. The approval of additional indications will further boost sales.

Auxilium Pharma currently carries a Zacks Rank #2 (Buy). Some other stocks worth considering in the pharma sector include Shire (SHPG - Analyst Report) and Jazz Pharmaceuticals (JAZZ - Analyst Report). Both carry a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%